



Antitumor agents 273. Design and synthesis of *N*-alkyl-thiocolchicinoids as potential antitumor agents [☆]

Takashi Kozaka ^a, Kyoko Nakagawa-Goto ^a, Qian Shi ^a, Chin-Yu Lai ^a, Ernest Hamel ^b, Kenneth F. Bastow ^c, Arnold Brossi ^a, Kuo-Hsiung Lee ^{a,*}

^a Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA

^b Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Institutes of Health, Frederick, MD 21702, USA

^c Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA

ARTICLE INFO

Article history:

Received 5 March 2010

Revised 17 May 2010

Accepted 19 May 2010

Available online 24 May 2010

Keywords:

N-Alkylthiocolchicinoids

Antitumor agents

Tubulin polymerization

ABSTRACT

As a part of our continuing study of colchicinoids as therapeutically useful antitumor drugs, thiocolchicine derivatives, including their phosphate and other water soluble salts, were synthesized and evaluated for inhibition of tubulin polymerization and for in vitro cytotoxicity. Three compounds, **7**, **10**, and **11**, showed potent inhibition of tubulin assembly ($IC_{50} = 0.88\text{--}1.1\ \mu\text{M}$). In addition, compound **7**, a water soluble succinic acid salt of *N*-deacetylthiocolchicine (**4**), showed potent cytotoxicity against a panel of tumor cell lines, suggesting it might be a potential lead to be developed as a therapeutic antitumor agent. Compound **8**, a water soluble succinic acid salt of *N,N*-dimethyl-*N*-deacetylthiocolchicine (**5**), showed selective activities against HCT-8 and SK-BR-3 cells. *N,N*-Diethyl-*N*-deacetylthiocolchicine (**6**) seemed not to be a substrate for the P-gp efflux pump, based on the similar ED_{50} values obtained against P-gp over-expressing KBvin (0.0146 $\mu\text{g/mL}$) cells and the parent KB (0.0200 $\mu\text{g/mL}$) cell line.

© 2010 Elsevier Ltd. All rights reserved.

Colchicine (**1**, Fig. 1), an alkaloid isolated from *Colchicum autumnale* and *Gloriosa superba*, is known to possess notable anti-inflammatory, anti-mitotic, and anti-fibrotic effects.² Although colchicine has significant in vitro antitumor effects, its medicinal uses, as well as use of its derivatives, has been limited because of high toxicity, low bioavailability, and poor water solubility.³ Thiocolchicine (**2**), originally derived from colchicine by semi-synthesis, possesses comparable or greater biological activity than colchicine (**1**) and has been studied for many years.² Although **2** is structurally more stable than **1**, its substantial toxicity and poor water solubility limit interest in it as a drug candidate. Many efforts have been made to develop thiocolchicine analogs with the goal of reducing toxicity and increasing watersolubility.^{3,4} 2-Demethylthiocolchicine (**3**) was found to be slightly less active but also less toxic than **2** and **1**.⁵ *N*-Deacetylthiocolchicine (**4**) was previously synthesized and was similar to **2** in its inhibitory effect on tubulin assembly.⁶ These findings suggested that further modifications could lead to more active compounds with reduced toxicity or greater water solubility and thus have greater potential as drug candidates.

The preparation of di-alkyl-substituted amines of *N*-deacetylthiocolchicine (**4**) and related pharmaceutically and clinically accepted salts and phosphate derivatives has not been described.

In this Letter, we report such modifications of thiocolchicine and its derivatives at the amino group at C_7 and at the hydroxy group at C_2 of **3** and **4**.

Treatment of **4**⁶ with formaldehyde and acetaldehyde in the presence of NaBH_3CN under acidic conditions yielded *N,N*-dimethyl- (**5**) and *N,N*-diethyl-*N*-deacetylthiocolchicine (**6**) in 80% and 82% yields, respectively, without obtaining *N*-mono-alkyl-substituted compounds (Scheme 1). Amines **4**–**6** were converted to corresponding succinic acid salts **7**–**9** in quantitative yields.

A series of *N*-mono-alkylated analogs of **4** was synthesized through ready addition and removal of the *o*-nitrobenzenesulfonamide (*o*-Ns) group, which is widely tolerant of basic and acidic conditions (Scheme 2). According to Fukuyama's protocol,⁷ **4** was





Figure 1.


[☆] For part 272 of this series, see Ref. 1.

* Corresponding author. Tel.: +1 919 962 0066; fax: +1 919 966 3893.

E-mail address: khlee@unc.edu (K.-H. Lee).



Scheme 1. Reagents and conditions: (a) RCHO (R = H or Me), NaBH₃CN, HOAc, CH₂Cl₂, **5**; 80% (R' = Me); (b) succinic acid, acetone, **7**, **8**, **9**; quant.



Scheme 2. Reagents and conditions: (a) *o*-NsCl, 2,6-lutidine, CH₂Cl₂; (b) RI (R = Me, Et or Pr), K₂CO₃, MeCN **11**; 85%, **12**; 97%; **13**; 53%; (c) BBr₃, CH₂Cl₂, –78 °C, 75%; (d) thioglycolic acid, Et₃N, CH₂Cl₂, 59%; (e) POCl₃, Et₃N, MeCN, 0 °C to rt; then H₂O, pyridine, 43%; (f) succinic acid, acetone, quant.

converted to *N*-[*o*-Ns]-*N*-deacetylthiocolchicine (**10**) with *o*-NsCl in the presence of 2,6-lutidine in CH₂Cl₂, followed by alkylation with RI (R = Me, Et or Pr) in the presence of K₂CO₃ in MeCN to afford **11**, **12** and **13** in 72%, 97% and 53% overall yields, respectively. Treatment of **11** with BBr₃ in CH₂Cl₂ at –78 °C succeeded in the regioselective demethylation to afford **14** in 75% yield, while the reported method⁸ by heating with H₂SO₄ gave a lower yield of the desired compound. The *o*-Ns group was removed from **14** with thioglycolic acid and Et₃N in CH₂Cl₂ to obtain the secondary amine **15** in 59%

yield. Compound **16**, a phosphate of **15**, was synthesized by using POCl₃ in MeCN and purified with reverse phase column chromatography (MeOH–H₂O). Treatment of **15** with succinic acid in acetone gave **17**. The water solubility at room temperature of analogs **7–9**, **16**, and **17** were 180 mg/mL, 103 mg/mL, 107 mg/mL, 15 mg/mL and 95 mg/mL, respectively.

All newly synthesized compounds were evaluated for effects on tubulin assembly and in vitro antitumor activities against several tumor cell lines. Studies were also performed with colchicine (**1**),

Table 1
Inhibition of tubulin assembly of 2–17

Compound	Inhibition of tubulin assembly IC ₅₀ (μM) ± SD	Inhibition of colchicine binding % Inhibition ± SD	
		5 μM	50 μM
2	0.77 ± 0.2	74 ± 2	ND ^a
4	0.91 ± 0.05	63 ± 1	ND
5	2.5 ± 0.3	42 ± 4	88 ± 0.6
6	5.4 ± 0.2	31 ± 3	84 ± 3
7	0.88 ± 0.03	64 ± 2	ND ^a
8	3.6 ± 0.04	27 ± 4	85 ± 0.1
9	16 ± 1	17 ± 6	65 ± 1
10	1.1 ± 0.06	58 ± 2	ND
11	0.92 ± 0.03	43 ± 3	60 ± 2
12	4.2 ± 0.7	22 ± 5	26 ± 5
13	>40	ND ^a	ND
14	3.6 ± 0.2	20 ± 7	34 ± 6
15	>40	ND	ND
16	>40	ND	ND
17	23 ± 1	ND	ND
CA ^b	1.2 ± 0.2	99 ± 1	ND

^a Not done.^b Combretastin A-4: positive control.

thiocolchicine (**2**), and *N*-deacetylthiocolchicine (**4**). The cell line panel included KB (human epidermoid carcinoma of the nasopharynx), HCT-8 (human ileocecal carcinoma), A549 (human lung adenocarcinoma), DU145 (human prostate carcinoma), SK-BR-3 (human breast cancer) and KBvin (vincristine-resistant line derived from the KB cell) cells. In addition, the most active inhibitors of tubulin assembly were also evaluated as inhibitors of the binding of [³H]colchicine to tubulin. The tubulin data are summarized in Table 1. Relative to the activity shown by **2** and **3**, *N,N*-dimethyl- (**5**) and *N,N*-diethyl-*N*-deacetylthiocolchicine (**6**), derived from **4** by alkylation, exhibited reduced activity as inhibitors of both tubulin assembly and colchicine binding. Compounds **7**, **8**, and **9** are three succinic acid salts of **4**, **5**, and **6**. Compound **7**, derived from *N*-deacetylthiocolchicine (**4**), had activity comparable with that of its parent compound **4**, while compounds **8** and **9**, salts of **5** and **6**, were somewhat less potent than their parent compounds. *N*-*o*-Ns substituted compounds **10** and **11**, with no other *N*-alkyl (**10**) or a methyl substituent (**11**) in addition to the *o*-Ns group, also displayed potent anti-tubulin activities. However, replacing the methyl group with an ethyl (**12**) or propyl (**13**) moiety led to reduced or lost activity relative to compound **11** in the tubulin assays. This suggests that the size of alkyl groups at the C₇-amino position of *N*-deacetylthiocolchicines may play a role in the interaction of these compounds with the binding site of the target protein, while the *o*-Ns group may not significantly affect anti-tubulin activity.

2-Demethylthiocolchicine (**3**) was previously reported as an active inhibitor of tubulin assembly and colchicine binding.³ However, in our recent study, a series of 2-demethyl-*N*-deacetylthiocolchicine derivatives (**14**–**17**) showed reduced activity against tubulin assembly. Compared with the parent compound **11**, compound **14**, the 2-demethyl derivative of **11**, was about four times less active against tubulin assembly (IC₅₀ = 3.6 μM) and half as potent in inhibition of colchicine binding (20% inhibition of colchicine binding). Compound **15**, the *N*-de-*o*-Ns analog of compound **14**, showed remarkably reduced activity as an anti-tubulin agent, since it was essentially inactive as an inhibitor of tubulin assembly (IC₅₀ >40 μM). These findings suggest that a trimethoxyphenyl moiety with its lipophilic molecular feature may be required for *N*-deacetylthiocolchicines to fit into a hydrophobic pocket in the binding site. The acetamido group at C₇ of compound **3** may play a role in maintaining the drug molecule in a suitable conformation to interact with the target protein. Although the

hydroxy group at C₂ of compound **16** was masked with a phosphoryl moiety, the highly polar and H-bonding properties of the phosphate moiety may prevent the molecule from interacting optimally with the colchicine-binding domain and thereby eliminating its anti-tubulin activity (IC₅₀ >40 μM).

In vitro antitumor activities of the newly synthesized compounds were evaluated, and the results are summarized in Table 2. Consistent with the tubulin data discussed above, **5** and **6**, *N,N*-deacetylthiocolchicine derivatives with *N,N*-di-alkyl substituents at C₇, were on average ten times more active than the non-alkyl substituted compound **4**. The *N,N*-diethyl compound **6** generally had antiproliferative activity similar to that of the *N,N*-dimethyl compound **5** and colchicine (**1**). Compound **6** was the only highly active agent tested that was equally active against the vincristine resistant, MDR nasopharyngeal cancer cell line (KBvin) as the parental non-MDR KB cell line. This result suggests that the size of *N*-alkyl substituent at C₇ may affect recognition of a colchicinoid by P-glycoprotein and/or the mechanism of action of **6** may be other than inhibition of tubulin activity. Although, in general, the succinic acid salts, **7**–**9**, showed decreased activities relative to their parent compounds **4**–**6**. *N,N*-dimethyl compound **8** was selectively more potent against HCT-8 (ED₅₀ = 0.0220 μg/mL) and SK-BR-3 (ED₅₀ = 0.0129 μg/mL) than its parent compound **5**, and **8** was 10-fold more cytotoxic against other tested cell lines. The cytotoxicity of *N*-*o*-Ns-*N*-deacetylthiocolchicine derivatives, **10**–**13**, revealed the same tendency as described above. In summary, the smaller alkyl substituents on the amino group at the C₇-position tended to have stronger activities against all cell lines (**10**, R = H > **11**, R = Me > **12**, R = Et > **13**, R = Pr). *N*-Non-alkyl-substituted *N*-[*o*-Ns] compound **10** showed the highest activity among **10**–**13** against all tested cell lines (ED₅₀ = 0.0100–0.0270 μg/mL). Although 2-demethylthiocolchicine (**3**) showed similar activity to thiocolchicine (**2**) (ED₅₀ = 0.01 μg/mL against A549, 0.01 μg/mL against KB),³ the cytotoxic potency decreased for the 2-demethyl-*N*-[*o*-Ns]-*N*-deacetylthiocolchicine series (e.g., **11** vs **14**), as occurred in the tubulin assay. Differing from the tubulin assay results, compound **15**, derived from **14** by removal of the *o*-Ns protection group, did not show significant loss in inhibition of tumor cell growth. In addition, the inhibitory activity toward DU145

Table 2
In vitro anticancer activity data of 1–17

Compounds	ED ₅₀ (μg/mL) ^a /cell line ^b					
	HCT-8	A549	DU145	SK-BR-3	KB	KBvin
1	0.0540	0.0199	0.0027	0.0027	0.0038	0.1578
2	0.0080	0.0019	0.0012	0.0015	0.0008	0.0147
4	0.0050	0.0077	0.0018	0.0016	0.0018	0.0139
5	0.0380	0.0476	0.0180	0.0179	0.0270	0.0413
6	0.0310	0.0193	0.0138	0.0141	0.0200	0.0146
7	0.0291	0.0256	0.0185	0.0115	0.0080	0.0330
8	0.0220	0.1902	0.1243	0.0129	0.1200	0.1250
9	0.1100	0.1808	0.1249	0.1361	0.0630	0.1512
10	0.0270	0.0209	0.0129	0.0126	0.0100	0.1120
11	0.1200	0.1288	0.0312	0.0285	0.0350	0.1526
12	0.5200	0.2116	0.1630	0.1482	0.1300	0.1737
13	>1.000	1.6330	0.3574	0.6155	0.9600	1.3626
14	>1.000	1.6791	1.1483	1.0118	0.7200	1.4892
15	>1.000	1.5474	0.5054	0.4874	0.5500	1.3798
16	>1.000	0.5332	0.1572	0.1368	0.2500	1.7062
17	>1.000	1.2599	0.3420	0.3899	0.3500	1.3456

^a Mean concentration giving 50% inhibition of cell growth following two days continual exposure (three replicates varied less than 5% between and within experiments).^b HCT-8 = human ileocecal carcinoma cell line, A549 = human lung adenocarcinoma epithelial cell line, DU145 = human prostate carcinoma cell line, SK-BR-3 = human breast cancer cell line, KB = human epidermoid carcinoma of the nasopharynx, KBvin = vincristine-resistant nasopharyngeal cancer cell line derived from the KB line.

and SK-BR-3 cells slightly increased. Compound **16**, a phosphate of **15**, showed two-three times more potent cytotoxicity than **15** against A549, DU145, SK-BR-3, and KB cell growth, suggesting that the phosphate group may increase selectivity to the target tumor cells. Notably, the new compounds, *N,N*-dialkyl-*N*-deacetylthiocolchicines, **5** and **6**, as well as the succinates, **7–9**, showed comparable or better cytotoxicity against P-gp over-expressing KBvin cells than colchicine.

In summary, modifications of the amino group at C₇ and the methoxy group at C₂ of *N*-deacetylthiocolchicine (**4**) were achieved. Two *N,N*-di-alkyl-*N*-deacetylthiocolchicine derivatives, **5** and **6**, corresponding succinates **7–9**, *N*-[*o*-Ns]-*N*-deacetylthiocolchicines **10–13**, and 2-demethyl-*N*-methyl-*N*-deacetylthiocolchicines **14** and **15**, salt **17**, and C₂-phosphate **16** were generated. We analyzed this series of compounds for their anti-tubulin activity and in vitro cytotoxicity. Although none of the newly synthesized compounds showed more potent activity than their parent compound **4** or thiocolchicine (**2**), the succinic acid salts, especially compound **7**, have potential as promising antitumor agents, because of both their excellent antiproliferative activity and their superior water solubility. The size of the *N*-substituted alkyl groups played a role in inhibition of tubulin assembly and colchicine binding and in vitro cytotoxicity. Generally, the larger alkyl substituents showed reduced activity against both tubulin and tumor cell growth. *N,N*-Diethyl analog **6**, however, showed more potent cytotoxicity than its *N,N*-dimethyl counterpart, which differed somewhat from the tubulin results. This result may indicate an additional mechanism of action for **6** versus **5**. In addition, compound **6** also showed higher potency against the KBvin cell line relative to the parental KB line. Thus,

compound **6** may merit further investigation to understand its apparent resistance to the P-gp efflux pump. Finally, the succinic acid salt of *N,N*-dimethyl-*N*-deacetylthiocolchicine, compound **8**, showed selective activities against HCT-8 and SK-BR-3 cells.

Acknowledgment

This study was supported by NIH grant CA17625 from the National Cancer Institute awarded to K. H. Lee.

References and notes

1. Dong, Y.; Shi, Q.; Pai, H. C.; Peng, C. Y.; Pan, S. L.; Teng, C. M.; Nakagawa-Goto, K.; Yu, D.; Liu, Y. N.; Wu, P. C.; Bastow, K. F.; Morris-Natschke, S. L.; Brossi, A.; Lang, J. Y.; Hsu, J. L.; Hung, M. C.; Lee, E. Y.; Lee, K. H. *J. Med. Chem.* **2010**, *53*, 2299.
2. (a) Capraro, H. G.; Brossi, A. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: New York, 1984; Vol. 23, p 1. and references cited therein; (b) Boyé, O.; Brossi, A. In *The Alkaloids*; Brossi, A., Cordell, G. A., Eds.; Academic Press: New York, 1992; Vol. 41, p 125. and references cited therein; (c) Brossi, A. *J. Med. Chem.* **1990**, *33*, 2311; (d) Zhang, S. H.; Feng, J.; Kuo, S. C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K. H. *J. Med. Chem.* **2000**, *43*, 167.
3. Nakagawa-Goto, K.; Chen, C. X.; Hamel, E.; Wu, C. C.; Bastow, K. F.; Brossi, A.; Lee, K. H. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 235.
4. Muzaffar, A.; Brossi, A.; Lin, C. M.; Hamel, E. *J. Med. Chem.* **1990**, *33*, 567.
5. (a) Velluz, L.; Muller, G. *Bull. Soc. Chim. Fr.* **1954**, 1072; (b) Huant, E. *Therapie* **1955**, *10*, 448.
6. Shi, Q.; Verdier-Pinard, P.; Brossi, A.; Hamel, E.; Wu, C. C.; Lee, K. H. *Bioorg. Med. Chem.* **1997**, *5*, 2277.
7. (a) Fukuyama, T.; Jow, C. K.; Cheung, M. *Tetrahedron Lett.* **1995**, *36*, 6373; (b) Cifuentes, M.; Schilling, B.; Ravindra, R.; Winter, J.; Janik, M. E. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2761.
8. Kerkes, P.; Sharma, P. N.; Brossi, A.; Chignell, C. F.; Quinn, F. R. *J. Med. Chem.* **1985**, *28*, 1204.